Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375946 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers
A Phase 1 study, sponsored by Agile Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01375946 is a Phase 1 study that has completed, run by Agile Therapeutics. The registered enrollment target is 24 participants.
The verdict
NCT01375946, a Phase 1 study, has completed, sponsored by Agile Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
A study to evaluate pharmacokinetic profile, wearability and safety of AG200-15, transdermal delivery of levonorgestrel (LNG) and ethinyl estradiol (EE), under normal conditions and external conditions of heat, humidity, cold water and exercise.
Interventions
- DRUG AG200-15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01375946
The ClinicalTrials.gov registry entry for NCT01375946 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agile Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG200-15 is the first listed.
NCT01375946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01375946 about?
NCT01375946 is a clinical study titled "Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers". A study to evaluate pharmacokinetic profile, wearability and safety of AG200-15, transdermal delivery of levonorgestrel (LNG) and ethinyl estradiol (EE), under normal conditions and external conditions of heat, humidity, cold water and exercise.
What is the current status of trial NCT01375946?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-05. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01375946?
The interventions under investigation include: AG200-15 (DRUG).
Who is sponsoring clinical trial NCT01375946?
This trial is sponsored by Agile Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.